GlassScriptPhysician profile
Orelia B Wood
NPI 1316417470
$6,708.02
in general payments reported to CMS, 2019-2025
36 companies · $720 in 2025
The $720 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,025 · 2022: $2,038 · 2023: $1,793 · 2024: $1,133 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,645.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,113.68 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Abbvie INC. | $873.70 | 2022-2024 | |
| Esperion Therapeutics, INC. | $351.72 | 2021-2022 | |
| Sobi, INC | $249.38 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $225.60 | 2021-2022 | |
| Daiichi Sankyo INC. | $223.32 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.86 | 2023-2024 | Fruzaqla, Livtencity |
| Novo Nordisk INC | $179.08 | 2024 | |
| Stemline Therapeutics INC. | $155.20 | 2021 | |
| Ferring Pharmaceuticals INC. | $152.48 | 2023 | Rebyota |
| Genzyme Corporation | $135.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.98 | 2023 | |
| Incyte Corporation | $124.96 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $123.63 | 2024 | |
| Pharmacosmos Therapeutics INC. | $122.10 | 2022 | |
| Kite Pharma, INC. | $121.86 | 2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $121.84 | 2024 | Koselugo |
| Genentech USA, INC. | $120.88 | 2023 | |
| Kyowa Kirin, INC. | $120.64 | 2024 | |
| Janssen Pharmaceuticals, INC | $120.14 | 2021 | |
| Sun Pharmaceutical Industries INC. | $119.94 | 2024 | |
| Pfizer INC. | $119.21 | 2024 | |
| Myovant Sciences INC. | $116.42 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $112.96 | 2022 | |
| Ascendis Pharma Endocrinology INC | $112.01 | 2025 | Yorvipath |
| Syndax Pharmaceuticals, INC. | $106.19 | 2025 | Revuforj |
| Astellas Pharma US INC | $104.46 | 2023 | |
| Gilead Sciences, INC. | $103.79 | 2024 | Vemlidy |
| Pharmaessentia USA Corporation | $103.16 | 2022 | |
| Organon LLC | $101.80 | 2025 | Vtama |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $96.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $95.32 | 2022 | |
| Celgene Corporation | $89.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orelia Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.